EPIDEMIOLOGICAL ANALYSIS AND TIME PREDICTION MODELS OF CORONAVIRUS (COVID-19/SARS-COV-2) SPREAD IN SELECTED EPICENTERS AROUND THE WORLD; NIGERIA AS CASE STUDY

Favour Deborah A. Onyelowe[1*] & Kennedy C. Onyelowe[2]

[1]Department of Biotechnology, Faculty of Science, Ebonyi State University, Abakaliki, Ebonyi State, Nigeria.
[2]Department of Mechanical and Civil Engineering, School of Engineering and Applied Sciences, Kampala International University, Kampala, Uganda.

ABSTRACT*: The spread of coronavirus disease (COVID-19/SARS-CoV-2) in Nigeria from index to community cases is becoming alarming that what the future holds should be brought to bear. An analytical study and time prediction model have been conducted on the epidemiological spread of coronavirus (COVID-19/SARS-CoV-2) with data collected from records of selected epicenters in Nigeria. The data was collected between March 1 and May 31, 2020. It can be shown that the highest daily infection in March was recorded on the 28th with 32 infections while the highest fatality rate was recorded on 24th with a rate of 2.3% and recorded daily infection of 10. As at the 31st, a total number of 139 confirmed cases were recorded in Nigeria with a fatality and discharge rates of 1.4 and 6.5% respectively. It can be deduced that the highest daily infection in Nigeria in the month of April was recorded on 30th, with daily infection of 204 confirmed cases. A highest discharge rate of 34.4% was recorded on 16th, with a fatality rate of 2.9% while the highest fatality rate of the month of April was 3.5% recorded on 18th, which has a discharge rate of 30.6% and a daily infection record of 49. As at April 30, 2020, Nigeria had recorded a total of 1932 confirmed cases with 58 deaths. It can also be deduced that the highest daily infection in Nigeria in the month of May was recorded on 30th, with daily infection of 553 confirmed cases. It can also be observed that the highest discharge and fatality rates for the month of May 2020 are 29.6% and 3.6% recorded on 31st and 2nd respectively. As at May 31, 2020, the total infection stood at 10162 confirmed cases and there seems to be a continuing upward trajectory for the situation under investigation. It can also be observed that the rate of discharged cases continued to surpass those of the fatality for the months of investigation. No doubts that the COVID-19/SARS-CoV-2 was first recorded in Ogun state of Nigeria, but Lagos state has surpassed both the daily infections and the cumulative infections for the country. With collected data, MLR simple linear regression extension was used to estimate an outcome or target variable on the basis of two or more independent variables. The variables which are the three months data collected from daily infections, total confirmed case, total deaths and total discharged cases between March 1, 2020 and May 31, 2020 were used to propose regression equations for the prediction of the cases under study for anytime period.*

KEYWORDS: Coronavirus (COVID-19/SARS-CoV-2); Time Prediction Model; Epidemiological Spread; Epicenter of Viral Infection; Confirmed Cases; % Discharged Cases; Intravascular Coagulation; Biomedicine; Pneumonia; Symptomatic Infections; Asymptomatic Infections; Community Infections.

INTRODUCTION

Coronavirus disease is a potentially severe acute respiratory infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). According to WHO, 44 cases of pneumonia of unknown microbial etiology entangled with Wuhan city, Hubei province china on 31 December 2019 (C. Sohrabi *et al*. 2020; CCDCP, 2020). According to N. J. Beeching *et al*. 87% of confirmed cases were aged 30 to 79 years, 1% were aged 80 years or older. Approximately 51% of patients were male and 49% were female. In the US older patients aged greater than or equal to 65 years accounted for 31% of all cases, 45% of hospitalizations, 53% of intensive care unit admissions and 80% of deaths, with the highest incidence of severe outcomes in patients aged greater than or equal to 85 years (Francesco *et al*. 2020). According to findings, weather conditions may influence the transmission of COVID-19, with cold and dry conditions appearing to increase transmission, and warm and humid conditions reducing risk of cases and deaths in some countries (Hussin *et al*. 2020). Most common symptoms of COVID-19 include fever, cough, dyspnea, myalgia, fatigue, altered sense of taste/smell, while less common symptoms include sore throat, confusion, dizziness, headache, rhinorrhea, or nasal congestion, hemoptysis, chest pain, conjunctivitis, cutaneous manifestations (K. Sun *et al.* 2020), (see Fig. 1). Approximately 90% of patients present with more than one symptom, and 15% of patients present with fever, cough, and dyspnea. On January 7, a novel coronavirus was identified by the Chinese center of Disease control and prevention (CDC) from the throat swap sample of a patient and was subsequently named 2019-nCoV by WHO (CCDCP, 2020; C. Sohrabi *et al*. 2020). According to D. Isaacs *et al.* (1983), COVID-19 can cause multiple system infections in respiratory tract infections in humans, such as Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). The following research was carried out in china on patients with SARS-CoV-2 according to age. 10 (10%) of these patients were less than or equal to 39 years old, 22 (22%) of these patients were 40-49 years old, 30 (30%) of these patients were 50-59 years old, 22 (22%) of these patients were 60-69 years old, 15 (15%) of these patients were greater than or equal to 70 years old. The same research was carried out according to sex. There were 32 (32%) of female patients and 67 (68%) of male patients.

Fig. 1 COVID-19/SARS-CoV-2 origin, infectious and effect factors on humans (D. Isaacs *et al*. 1983)

LITERATURE REVIEW

Epicentres/severely affected countries on epidemiological spread of COVID-19/SARS-CoV-2 across continents

According to S. Ma *et al*. between late February and early march of 2020, the individual data of laboratory confirmed cases of COVID-19 were retrieved from 10728 publicly available reports released by the health authorities of and outside china and from 1790 publications identified in PubMed and CNKI. According to Steffens, Europe has become the new epicenter of the COVID-19 pandemic. Italy was initially the county hit the hardest by far Spain, the Netherlands and other followed. France and Germany had experienced the first importation of cases already in January. On 10 March, the total number of fatalities in Italy exceeded 3,000, topping the total number of

reported fatalities in china. Outside Europe, Iran faced a rapid surge of COVID-19 followed by exportation of cases mostly to countries in the Middle East (N. Chen *et al*. 2020). The United States in North America, and the Europe in United Kingdom emerged as new epicenter with 124,655 cases plus 1,019 fatalities respectively, reported by 29 March (PHAC, 2020). Recently increasing case numbers have also been seen in Africa and in Asian countries outside China (R. Lu *et al*. 2020).

While exploring the long -term effects of COVID -19 , Benda *et al*. (2021) provide a comprehensive review of various diagnostic technologies used in the context of COVID -19 testing, including molecular tests, rapid antigen tests, and serology tests. Their study emphasizes the significance of accurate reporting of test results and their integration into epidemiological studies . Furthermore , they discuss the potential utility of saliva samples for testing and the availability of at-home collection kits. This research is invaluable in understanding the evolving landscape of COVID -19 diagnostics and the broader implications for long-term patient care (Benda *et al.* 2021).

COVID-19 Time line showed that from December 31-January 3, 2020, 44 cases of pneumonia of unknown cause was reported in Wuhan (Steffens, 2020; N. Chen *et al*. 2020). On January 7, 2020, new coronavirus was identified. On January 13, 2020: Thailand, on January 15, 2020: Japan, on January 20, 2020: South Korea, on January 23, 2020: United States and on April 4, 2020, worldwide cases surpassed 1 million (S. Ma *et al*. 2020). The novel COVID-19 was declared a global pandemic by World Health Organization (WHO) on the 11 March 2020. The WHO has reported an incubation period for COVID-19 between 2 and 10 days. However according to research incubation period can last for longer than two weeks. However, according to N. Chen *et al*. (2020) and Sasmita *et al*. (2020), cases reported in china according to location and patients include; Mainland china - 364(72%), Beijing - 133(26%), Shaanxi - 87(17%), Hubei - 41(8%), Tlanjin - 22(4%), Yunnan - 19(4%). And the mortality rate around the world vary by country as

of first week of April 2020 as follows; China - 4.0%, South Korea - 1.8%, Italy - 12.5%, Spain - 9.7%, Iran - 6.2%, United States - 3.2%, worldwide - 5.6%. As of April 7th 2020, 1,353,361 confirmed cases worldwide, 79,235 confirmed deaths, 212 counties, areas or territories with cases.

Epicentres/severely affected states on epidemiological spread of COVID-19/SARS-CoV-2 Nigeria

Report has shown that coronavirus is one of the major pathogens that mainly targets the human respiratory system (Yan-Rong *et al*. 2020). The first case of COVID-19 was reported in December 2019. From December 18, 2019 through December 29, 2019, five patients were hospitalized with acute respiratory distress syndrome. By January 2, 2020, 41 admitted hospital patients had been identified as having laboratory confirmed COVID-19 infections, less than half of the patients had underlying diseases including diabetes, hypertension, and cardiovascular diseases. Different bodies including the WHO and the US Center for Disease Control and Preventions (CDC) have issued advice on preventing further spread of COVID-19. They have advised that travel to high risk areas should be avoided, and contact with patients who are symptomatic should also be avoided. Basic hand hygiene measures are also recommended including frequent hand washing. The SARS-CoV-2 possesses a single strand, positive sense RNA genome ranging from 26-32 kilobases in length. Coronavirus has been identified in various mammals including camels, bats, masked palm civets, mice, dogs and cats. The COVID-19/SARS-CoV-2 was first recorded in Ogun state of Nigeria, but Lagos state has surpassed both the daily infections and the cumulative infections for the country. On May 30, 2020, Lagos state recorded a daily total of 378 confirmed cases and Kano state has continued to follow in the rate at which cases are confirmed in Nigeria and followed by the other 8 states. Also beyond these 10 states in view, the tide is changing towards the south-south and south-east regions of Nigeria and this demands urgent study.

METHODOLOGY

Data Collection
The data for this work was collected using sampling method and released information from the WHO, CDC and NCDC on a daily monitoring of the recorded cases of events across the world and particularly Nigeria. The collation of the data took three months spanning between March 1 and May 31, 2020. The cumulative daily cases of infection, discharged and deaths were collated and the rates of discharge and deaths were computed by common calculation. A literature search

was also incorporated and lastly a graphical analysis of the epidemiological spread of the COVID-19/SARS-CoV-2 was conducted.

Model Development and Statistical Hypothesis

MLR is a simple linear regression extension used to estimate an outcome or target variable on the basis of two or more independent variables. The expected parameter to be estimated is termed the dependent or outcome variable, which are total case discharged, total deaths and total case confirmed within a study time period. The variables or factors utilized to produce the estimation results are termed the predictor/independent/criterion variables or explanatory variables, which are the three months data collected from daily infections, total confirmed case, total deaths and total discharged cases between March 1, 2020 and May 31, 2020. MLR aids in the determination of the variance explained (overall fit) of the model in terms of respective contributions of each explanatory parameter to the total variance explained. It is also used to assess the relationship strength which exist between two or more variables and its respective target variables

The descriptive statistics of the data utilized for the model development which consist of epidemiological statistics of COVID-19/SARS-CoV-2 cases in Nigeria for three months duration is presented in Table 1;

Table 1. Statistical parameters of data sets for the model development

Model Variables	SE	Mean	SD	Range	SV	Minimum	Maximum
Duration	2.78	46.50	26.70	91	713.00	1	92
Daily infections	13.43	110.61	128.84	553	16601.03	0	553
% discharge	1.12	16.26	10.71	34.4	114.80	0	34.4
Total discharged	86.52	541.86	829.85	3007	688659.22	0	3007
Total deaths	9.17	65.90	87.96	287	7737.47	0	287
Total confirmed cases	309.33	2188.36	2966.98	10161	8802971.75	1	10162

Statistical Hypothesis

- Null Hypothesis: all the parameters of predictors are not significantly different from zeros which implies that the model is not statistically significant. This is expressed mathematically in Eqn. 1;

$$H_0 : \beta_1 = \beta_2...\beta_n = 0 \qquad (1)$$

- Alternate Hypothesis: at least one predictor parameter is significantly different from zero that is the model is statistically significant. This is expressed mathematically in Eqn. 2;

$$H_1 : \beta_1 \neq \beta_2...\beta_n \neq 0 \qquad (2)$$

RESULTS AND DISCUSSION

Epidemiological timeline of COVID-19/SARS-CoV-2 spread in Nigeria from March 1, 2020 to May 31, 2020.

Tables 1-3 and Figs. 2-7 represent the epidemiological timeline of COVID-19/SARS-CoV-2 spread in Nigeria from March 1, 2020 to May 31, 2020, which show the epidemiological statistics of COVID-19/SARS-CoV-2 cases and discharge and death rates in Nigeria within the studied period. It can be shown from Table 2 and Figs. 2 & 3 that the highest daily infection was recorded on the 28th of March with 32 infections while the highest fatality rate was recorded on March 24th with a rate of 2.3% and recorded daily infection of 10. As at the March 31, 2020 a total number of 139 confirmed cases were recorded in Nigeria with a fatality and discharge rates of 1.4 and 6.5% respectively. Table 3 and Figs. 4 & 5 present the studied cases for the month of April 2020. It can be deduced that the highest daily infection in Nigeria in the month of April was recorded on April 30, 2020 with daily infection of 204 confirmed cases. A highest discharge rate of 34.4% was recorded on April 16, with a fatality rate of 2.9% while the highest fatality rate of the month of April was 3.5% recorded on April 18, 2020, which has a discharge rate of 30.6% and a daily infection record of 49. As at April 30, 2020, Nigeria had recorded a total of 1932 confirmed cases with 58 deaths. Table 4 and Figs. 6 &7 present the studied cases for the month of May 2020. It can be deduced that the highest daily infection in Nigeria in the month of May was recorded on May 30, 2020 with daily infection of 553 confirmed cases. It can also be observed that the highest discharge and fatality rates for the month of May 2020 are 29.6% and 3.6% recorded on May 31,

2020 and May 2, 2020 respectively. As at May 31, 2020, the total infection stood at 10162 confirmed cases and there seems to be a continuing upward trajectory for the situation under investigation. From Figs. 3, 5 & 7, it can be observed that the rate of discharged cases continued to surpass those of the fatality for the months of investigation.

Table 2 March 2020 epidemiological statistics of COVID-19/SARS-CoV-2 cases in Nigeria

| Date	Total confirmed cases	Daily infections	Total discharged	% discharge	Total deaths	% deaths
1	1	1	0	0	0	0
2	1	0	0	0	0	0
3	1	0	0	0	0	0
4	1	0	0	0	0	0
5	1	0	0	0	0	0
6	1	0	0	0	0	0
7	1	0	0	0	0	0
8	1	0	0	0	0	0
9	1	0	0	0	0	0
10	2	1	0	0	0	0
11	2	0	0	0	0	0
12	2	0	0	0	0	0
13	2	0	0	0	0	0
14	2	0	0	0	0	0
15	2	0	0	0	0	0
16	3	1	1	33.3	0	0
17	3	0	1	33.3	0	0
18	8	5	1	12.5	0	0
19	12	4	1	8.3	0	0
20	12	0	1	8.3	0	0
21	22	10	2	9.1	0	0
22	24	2	2	8.3	0	0
23	33	9	2	6.1	1	3
24	44	10	2	4.5	1	2.3
25	51	7	2	3.9	1	2
26	65	14	3	4.6	1	1.5
27	65	0	3	4.6	1	1.5
28	97	32	3	3.1	1	1
29	111	14	3	2.7	1	0.9
30	131	20	8	6.1	2	1.5
31	139	8	9	6.5	2	1.4

Fig. 2 March 2020 epidemiological timeline of COVID-19/SARS-CoV-2 spread in Nigeria

Fig. 3 March 2020 epidemiological timeline of COVID-19/SARS-CoV-2 discharge and deaths rates in Nigeria

Table 3 April2020 epidemiological statistics of COVID-19/SARS-CoV-2 cases in Nigeria

| Date	Total confirmed cases	Daily infections	Total discharged	% discharge	Total deaths	% deaths
1	174	35	9	5.2	2	1.1
2	184	10	20	10.9	2	1.1
3	210	26	25	11.9	4	1.9
4	214	4	25	11.7	4	1.9
5	232	18	33	14.2	5	1.5
6	238	6	35	14.7	5	2.1
7	254	16	44	17.3	6	2.4
8	276	22	44	15.9	6	2.2
9	288	12	51	17.7	7	2.4
10	305	17	58	18.8	7	2.3
11	318	13	70	22.0	10	3.1
12	323	5	85	26.3	10	3.1
13	343	20	91	26.5	10	2.9
14	373	30	99	26.5	11	2.9
15	407	34	128	31.4	12	2.9
16	442	35	152	34.4	13	2.9
17	493	51	159	32.3	17	3.4
18	542	49	166	30.6	19	3.5
19	627	85	170	27.1	21	3.3
20	665	38	188	28.3	22	3.3
21	782	117	197	25.2	25	3.2
22	873	91	197	22.6	28	3.2
23	981	108	197	20.1	31	3.2
24	1097	116	208	19.0	32	2.9
25	1182	85	222	18.8	35	3.0
26	1273	91	239	18.8	40	3.1
27	1337	64	255	19.1	40	3.0
28	1532	195	255	16.6	44	2.9
29	1728	196	307	17.8	51	3.0
30	1932	204	319	16.5	58	3.0

Fig. 4 April 2020 epidemiological timeline of COVID-19/SARS-CoV-2 spread in Nigeria

Fig. 5 April 2020 epidemiological timeline of COVID-19/SARS-CoV-2 discharge and death rates in Nigeria

Table 4 May 2020 epidemiological statistics of COVID-19/SARS-CoV-2 cases in Nigeria

| Date	Total confirmed cases	Daily infections	Total discharged	% discharge	Total deaths	% deaths
1	2170	238	351	16.2	68	3.1
2	2388	218	358	15.0	85	3.6
3	2558	170	400	15.6	87	3.4
4	2802	244	417	14.9	93	3.3
5	2950	148	481	16.3	98	3.3
6	3147	197	534	17.0	103	3.3
7	3526	379	601	17.0	107	3.0
8	3912	386	679	17.4	117	3.0
9	4151	239	745	17.9	128	3.1
10	4399	248	778	17.7	143	3.3
11	4641	242	902	19.4	150	3.2
12	4787	146	959	20.0	158	3.3
13	4971	184	1070	21.5	164	3.3
14	5162	193	1180	22.9	167	3.2
15	5445	288	1320	24.2	171	3.1
16	5621	176	1472	26.2	176	3.1
17	5959	338	1594	26.7	182	3.1
18	6175	216	1644	26.6	191	3.1
19	6401	226	1734	27.1	192	3.0
20	6677	284	1840	27.6	200	3.0
21	7016	339	1907	27.2	211	3.0
22	7261	245	2007	27.6	221	3.0
23	7526	265	2174	28.9	221	2.9
24	7839	313	2263	28.9	226	2.8
25	8068	229	2311	28.6	233	2.9
26	8344	276	2385	28.6	249	3.0
27	8733	389	2501	28.6	254	2.9
28	8915	182	2592	29.1	259	2.9
29	9302	387	2697	29.0	261	2.8
30	9855	553	2856	29.0	273	2.4
31	10162	307	3007	29.6	287	2.8

Fig. 6 May 2020 epidemiological timeline of COVID-19/SARS-CoV-2 spread in Nigeria


Fig. 7 May 2020 epidemiological timeline of COVID-19/SARS-CoV-2 discharge and deaths rates in Nigeria

Epicentres/severely affected states of epidemiological spread of COVID-19/SARS-CoV-2 in Nigeria in May 2020.

Table 5 and Figs. 8 & 9 represent the epidemiological timeline of COVID-19/SARS-CoV-2 spread in the most affected states (epicenters) in Nigeria for the month of May 2020, which show the epidemiological statistics of COVID-19/SARS-CoV-2 daily infections within the studied period. No doubts that the COVID-19/SARS-CoV-2 was first recorded in Ogun state of Nigeria, but Lagos state has surpassed both the daily infections and the cumulative infections for the country. On May 30, 2020, Lagos state recorded a daily total of 378 confirmed cases as shown in Table 4 and Fig. 8. Kano state had continued to follow in the rate at which cases are confirmed in Nigeria and followed by the other 8 states as shown in Table 5.

Table 5 May 2020 epidemiological statistics of COVID-19/SARS-CoV-2 cases in 10 most severely affected states in Nigeria

Date	Lagos	Kano	FCT	Katsina	Bauchi	Borno	Ogun	Oyo	Jigawa	Kaduna
1	30	52	36	-	10	3	-	6	-	-
2	62	7	52	-	5	6	-	4	-	31
3	39	29	12	8	18	7	24	1	-	15
4	76	23	19	37	9	18	5	5	32	-
5	43	32	10	9	3	6	6	5	-	3
6	82	30	9	3	-	10	4	8	-	1
7	183	55	-	11	19	9	5	3	44	7
8	176	63	20	31	15	17	13	4	-	3
9	97	29	7	19	44	17	2	5	-	3
10	81	26	13	-	20	26	2	-	35	-
11	88	64	3	49	1	1	9	1	-	13
12	57	27	1	3	8	2	1	4	-	-
13	51	14	10	16	16	-	-	4	23	5
14	58	46	9	-	1	3	7	-	35	-
15	179	8	7	15	3	13	11	13	15	20
16	95	-	11	-	2	8	-	12	6	-
17	177	64	21	9	3	3	-	11	4	4
18	74	17	4	33	7	8	8	19	-	3
19	131	-	5	-	2	4	25	6	4	7
20	199	5	8	-	-	8	-	19	6	-
21	139	28	11	22	4	-	5	28	14	18
22	132	8	1	5	-	12	13	9	16	9

23	133	-	22	-	2	3	23	34	-	5
24	148	13	36	-	-	-	12	7	-	5
25	90	23	14	27	-	5	9	4	-	-
26	161	4	-	-	1	-	-	-	-	19
27	256	13	-	23	-	1	1	2	-	7
28	111	3	16	-	1	1	4	8	-	6
29	254	3	29	-	2	6	-	15	24	11
30	378	9	52	6	-	7	13	5	5	12
31	188	3	44	-	2	-	19	12	-	14

Fig. 8 May 2020 epidemiological statistics of COVID-19/SARS-CoV-2 cases in 10 most severely affected states in Nigeria

Fig. 9 May 2020 epidemiological statistics of COVID-19/SARS-CoV-2 cases in 10 most severely affected states in Nigeria without Lagos

Epidemiological Analytical Model Results and Validation

Analysis of Variance Result (ANOVA)

The data sets were statistically analyzed using ANOVA; the experimental duration, daily infections and percentage discharge are the predictor variables while the total discharged, total deaths and total confirmed cases are the target variables of the regression in the ANOVA, model independent variables were assessed with respect to the three response or outcome variables as shown in Tables 6, 7 and 8. The indices used for the statistical analysis are adjusted sum of square adjusted mean squares, and P-value. The adjusted mean square helps to evaluate the variation of a model or system predicts its response. It considers degree of freedom and provides platform for the computation of the adjusted coefficient of determination statistics (R^2-adj) presented in the model summary. The adjusted sum of squares helps to assess the variation measures of different model parameters without taken into account the order of the independent variables of the model. It is also utilized for the computation of the p-value of the factor levels and also the coefficient of the determination statistics (R^2); this is used together with the computed p-value for interpretation of model performance.

Table 6. Analysis of Variance for Total Discharged Response

Source	DF	Adj SS	Adj MS	F-Value	P-Value
Regression	3	45505763	15168588	77.78	0.000
Duration	1	875631	875631	4.49	0.037
Daily infections	1	3474712	3474712	17.82	0.000
% discharge	1	55333	55333	0.28	0.596
Error	88	17162226	195025		
Total	91	62667989			

Table 7. Analysis of Variance for Total Deaths Response

Source	DF	Adj SS	Adj MS	F-Value	P-Value
Regression	3	588680	196227	149.60	0.000
Duration	1	23005	23005	17.54	0.000
Daily infections	1	34200	34200	26.07	0.000
% discharge	1	997	997	0.76	0.386
Error	88	115430	1312		
Total	91	704110			

Table 8. Analysis of Variance for Total Confirmed Cases Response

Source	DF	Adj SS	Adj MS	F-Value	P-Value
Regression	3	659902403	219967468	137.12	0.000
Duration	1	20641294	20641294	12.87	0.001
Daily infections	1	44711208	44711208	27.87	0.000
% discharge	1	467384	467384	0.29	0.591
Error	88	141168026	1604182		
Total	91	801070429			

The P-value provides the criteria for rating of statistical significance within a hypothesis testing which shows where enough evidence exists for the acceptance or rejection of the conjecture or null hypothesis. For results interpretation, if P-value $> \alpha$ then we accept the null hypothesis which means that the corresponding factor is not an important predictor and possesses negligible value within the model but if P-value $> \alpha$ then we accept the alternate hypothesis which means that they are statistically significant to the prediction of the response parameter.From the computed results, % discharge factor has a p-value of 0.596, 0.386 and 0.591 for the three target responses respectively which indicated that the % discharge factor is not significant while the other factors; % confirmed and % deaths, in the predictor variables are statistically significant.

The Model Summary and Regression Coefficients

The developed regression model performance rating parameters are presented in the model summary for the derivation of the coefficient of determination (R^2) which is the variation (in percentage) in the outcome explained by the MLR model. It is used to determine how well the model fits the system data base; the higher the values, the better the model performance and its results ranges from minimum of 0% to maximum of 100% signifying that the fitted values are equal to the observed value.

Regression Equation

The regression equation helps to express the relationship between the dependent variable or model response and independent variables; it is expressed in algebraic form of a regression line which takes the form of;

$$y = \beta_0 + \beta_1 x_1 + ... + \beta_n x_n \tag{3}$$

Where y is the dependent or target variables, β_0 is the constant term, $\beta_1, \beta_2, ... \beta_n$ is the regression coefficients and $x_1, x_2, ... x_n$ is the independent or predictor variables. The model parameters are presented in Table 9

Table 9. MLR Model Parameters

Model Summary					Coefficients of Regression			
Response Parameters	*S*	*R^2 (%)*	*R^2-Pred (%)*	*R^2-adj (%)*	*Constant*	*Duration*	*Daily infections*	*% discharge*
Total discharged	441.617	72.61	69.55	71.68	-369	10.42	3.287	3.88
Total deaths	36.2174	83.61	81.81	83.05	-40.19	1.688	0.3261	-0.521
Total confirmed cases	1266.56	82.38	80.44	81.78	-1284	50.6	11.79	-11.3

The regression equations are presented in Eqns. 4, 5 and 6 for the three target parameters as follows;

$$TDs = -369 + 10.42\,D + 3.287\,DI + 3.88PD \qquad (4)$$

$$TDt = -40.19 + 1.688\,D + 0.3261\,DI - 0.521PD \qquad (5)$$

$$TCC = -1284 + 50.6\,D + 11.79\,DI - 11.3PD \qquad (6)$$

Where TDs is total discharge, TDt is total deaths, TCC is total confirmed cases, D is duration period, DI is daily infections, and PD is percentage discharge

Residual Plot

The residual plots show the residual values on the y-axis against the independent variable on the x-axis. The model residual results is obtained from the formular presented in Eqn. 7;

$$residual = observed - predicted \qquad (7)$$

Due to the fact that linear regression models are not always appropriate in terms of prediction performance, the evaluation of the appropriateness of the model is achieved by defining and examining the residual plots shown in Figs 10, 11 and 12. The plots presents the behavioral curves and Histogram charts of residuals which determine the skewness of the data under statistical examination; the normal probability plot of residuals which helps to verify the assumptions that residuals are normally distributed, the residual vs fit plot helps to verify that the residuals possess constant variance and residual versus order of data which helps to verify that the residuals are uncorrelated with each other.

Fig. 10. Residual Plots for Total discharged

Fig. 11. Residual Plots for Total deaths

Fig. 12. Residual Plots for Total confirmed cases

CONCLUSIONS

From the foregoing epidemiological analysis and time prediction models of coronavirus (COVID-19/SARS-CoV-2) spread in selected epicenters around the world with a focus on Nigeria case, it can be concluded with the following remarks;

(a) That the data of total confirmed cases, daily infections, daily discharge case, daily deaths, percentage discharge and deaths were successfully collected for the period of three months through releases from the Nigeria Centre for Disease Control (NCDC).

(b) That the collected data were analysed and results presented in graphs to show the behaviour of the virus spread within the period under investigation.

(c) That a time prediction model was conducted using the MLR and ANOVA algorithms to predict what would be the behaviour of the virus spread in Nigeria in any time period and the regression equations were proposed.

(d) That the proposed equations were validated as to established the functions that are more relevant to affect the results of the future predictions and this showed that total confirmed cases and total deaths are the independent variables that showed more effect on the suggested model expressions.

REFERENCES

C. Sohrabi, Zaid Alsafi, Niamh O'Neill *et al* (2020). World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). International Journal of Surgery, vol. 79, pp. 71-76. https://doi.org/10.1016/j.ijsu.2020.02.034

Chinese Center for Disease Control and Prevention (2020). The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. Chinese Center for Disease Control and Prevention Vol. 2 / No. 8

D. Isaacs, D Flowers, J R Clarke, *et al* (1983). Epidemiology of coronavirus respiratory infections, vl. 58, pp. 500-503

Francesco, D. G., Damiano Pizzol, Claudia Marotta *et al* (2020). Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review. International Journal of Environmental Research and Public Health, vol. 17, pp. 2690 https://doi:10.3390/ijerph17082690

Hussin, A. Rothan, and Siddappa N. Byrareddy (2020). The epidemiology and pathogenesis of coronavirus disease (COVID-19) Outbreak. Journal of Autoimmunity, vol. 109, pp. 102433. https://doi.org/10.1016/j.jaut.2020.102433

K. Sun, Jenny Chen, Cécile Viboud *et al* (2020). Early epidemiological analysis of the coronavirus disease 2019 outbreak based on crowdsourced data: a population-level observational study. Vol. 2, pp. 201–08. https://doi.org/10.1016/52589-7500(20)30026-1

N. Chen, Min Zhou, Xuan Dong *et al* (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. https://doi.org/10.1016/S0140-6736(20)30211-7

N. J. Beeching, Tom E. Fletcher, Robert Fowler *et al* (2020). Coronavirus disease 2019 (COVID-19). BMJ Best Practice.

Public Health Agency of Canada (2020). Coronavirus Disease 2019 (COVID-19) Daily Epidemiology Update. Public Health Agency of Canada.

Robert, Verity, Lucy C Okell, Ilaria Dorigatti *et al* (2020). Estimates of the severity of coronavirus disease 2019: a model-based analysis. https://doi.org/10.1016/s1473.3099(20)302437

R. Lu, Xiang Zhao, Juan Li *et al* (2020). Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. https://doi.org/10.1016/S0140-6736(20)30251-8

Sasmita, Poudel Adhikari, Sha Meng, Yu-Ju Wu *et al* (2020). Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infectious Diseases of Poverty, vol. 9, pp. 29. https://doi.org/10.1186/s40249-020-00646-x

S. Ma, Jiayue Zhang, Minyan Zen *et al* (2020). Epidemiological parameters of coronavirus disease 2019: a pooled analysis of publicly reported individual data of 1155 cases from seven countries. https://doi.org/10.1101/2020.03.21.20040329

Steffens, Ines (2020). A hundred days into the coronavirus disease (COVID-19) pandemic. Euro Surveill, vol. 25(14) pp. 2000550. https://doi.org/10.2807/1560-7917

Yan-Rong, Guo, Qing-Dong Cao, Zhong-Si Hong *et al (2020).* The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the Status. Military Medical Research, https://doi.org/10.1186/s40779-020-00240-0

Benda , Ashler , et al. "COVID -19 testing and diagnostics : a review of commercialized technologies for cost, convenience and quality of tests." Sensors 21.19 (2021): 6581., https://doi.org/10.3390/s21196581